Unicycive Therapeutics (UNCY) Shares Outstanding (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Shares Outstanding data on file, last reported at $25.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 110.75% year-over-year to $25.2 million; the trailing twelve-month figure through Mar 2026 stood at $25.2 million (up 110.75% YoY), and the FY2025 full-year result was $22.1 million, up 359468.94% from the prior year.
• Shares Outstanding for Q1 2026 stood at $25.2 million, up from $22.1 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $25.2 million in Q1 2026 and bottomed at $2265.0 in Q3 2025.
• The 5-year median for Shares Outstanding is $11.4 million (2024), against an average of $8.8 million.
• The widest annual swing landed in 2024, when Shares Outstanding slumped 99.97%; it then surged 359468.94% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $15.2 million in 2022, then plunged by 99.71% to $43649.0 in 2023, then tumbled by 85.91% to $6150.2 in 2024, then soared by 359468.94% to $22.1 million in 2025, then climbed by 14.12% to $25.2 million in 2026.
• The last three Shares Outstanding figures came in at $25.2 million (Q1 2026), $22.1 million (Q4 2025), and $2265.0 (Q3 2025), per Business Quant data.

Peer Comparison